|
|
Post by Clement on Jul 30, 2020 12:36:45 GMT -5
We also expect net gains in Tyvaso patients from our new Dreamboat product, which is completing its final stage of clinical development. And a pending new market approval for Tyvaso in WHO Group three PAH patients. That one now pending in front of the FDA. We also have very exciting pipeline extensions for Tyvaso in the field of COPD with our PERFECT study and in a non-pulmonary hypertension field interstitial lung disease with our new Phase III TETON study. finance.yahoo.com/m/ec401831-1635-3531-8786-7564a71b3a73/united-therapeutics-corp.html |
|
|
|
Post by boca1girl on Jul 30, 2020 13:05:12 GMT -5
We also expect net gains in Tyvaso patients from our new Dreamboat product, which is completing its final stage of clinical development. And a pending new market approval for Tyvaso in WHO Group three PAH patients. That one now pending in front of the FDA. We also have very exciting pipeline extensions for Tyvaso in the field of COPD with our PERFECT study and in a non-pulmonary hypertension field interstitial lung disease with our new Phase III TETON study. finance.yahoo.com/m/ec401831-1635-3531-8786-7564a71b3a73/united-therapeutics-corp.htmlI wouldn’t be surprised at all if UTHR buys out MNKD and licenses Afrezza to someone else. |
|
|
|
Post by awesomo on Jul 30, 2020 13:13:57 GMT -5
We also expect net gains in Tyvaso patients from our new Dreamboat product, which is completing its final stage of clinical development. And a pending new market approval for Tyvaso in WHO Group three PAH patients. That one now pending in front of the FDA. We also have very exciting pipeline extensions for Tyvaso in the field of COPD with our PERFECT study and in a non-pulmonary hypertension field interstitial lung disease with our new Phase III TETON study. finance.yahoo.com/m/ec401831-1635-3531-8786-7564a71b3a73/united-therapeutics-corp.htmlI wouldn’t be surprised at all if UTHR buys out MNKD and licenses Afrezza to someone else. Unfortunately this seems like the only good endgame result at this point. We seem to be completely reliant on UTHR for success. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 30, 2020 14:39:44 GMT -5
I wouldn’t be surprised at all if UTHR buys out MNKD and licenses Afrezza to someone else. Unfortunately this seems like the only good endgame result at this point. We seem to be completely reliant on UTHR for success. It will never happen. UTHR is happy with giving up 10% royalties and MNKD will take that money and sign up more partners for the TS Platform. TreT along with Afrezza will fund the business for now. There's more value in TS than for UTHR to own it. UTHR will not Expand TS...their plate is full and TS will not be a CORE Business for them. Once TreT is approved the floodgates will open for partner deals. I believe they are inquiring now and waiting for approval. And by that time the Terms become more favorable for MNKD. More upfront money and higher royalties. |
|
|
|
Post by sellhighdrinklow on Jul 30, 2020 15:25:36 GMT -5
"OUR new dreamboat..." ?
|
|
|
|
Post by gamblerjag on Jul 30, 2020 15:32:15 GMT -5
I saw that too “our” didn’t know if that was a slip or if they just figured they were working together… Hopefully it’s the former :-) |
|
|
|
Post by mango on Jul 30, 2020 17:15:44 GMT -5
I wouldn’t be surprised at all if UTHR buys out MNKD and licenses Afrezza to someone else. Unfortunately this seems like the only good endgame result at this point. We seem to be completely reliant on UTHR for success. And United Therapeutics seems to be completely reliant on MannKind for success with their inhaled treprostinil line (And potentially other pipeline candidates not yet disclosed). 😀 Win-win |
|
|
|
Post by awesomo on Jul 30, 2020 17:55:51 GMT -5
Unfortunately this seems like the only good endgame result at this point. We seem to be completely reliant on UTHR for success. And United Therapeutics seems to be completely reliant on MannKind for success with their inhaled treprostinil line (And potentially other pipeline candidates not yet disclosed). 😀 Win-win Yes, it is a win-win. The difference is, UTHR as a whole company is doing just fine with or without inhaled treprostinil. Whereas MannKind is just floundering around on their own. |
|
|
|
Post by buyitonsale on Jul 30, 2020 17:58:33 GMT -5
"new Dreamboat product" belongs to UTHR, they licensed it from MNKD to develop and market for $105M plus royalties.
|
|
|
|
Post by pat on Jul 30, 2020 18:22:44 GMT -5
I wouldn’t be surprised at all if UTHR buys out MNKD and licenses Afrezza to someone else. Unfortunately this seems like the only good endgame result at this point. We seem to be completely reliant on UTHR for success. I completely disagree with you. But then that’s why I continue to buy the stock. |
|
|
|
Post by sportsrancho on Jul 30, 2020 20:01:35 GMT -5
Nobody would buy us we have too much debt, the only thing to do is to keep swimming.
And nobody wants Afrezza because they haven’t proved it’s marketable. But that will change:-)
|
|
|
|
Post by georgethenight2 on Jul 31, 2020 1:33:59 GMT -5
At this point in my near decade long investment with MNKD I simply sit back and let the cards fall where they may. Previously super pumped for any news, but now nothing moves the needle, aside from sales and another drug on the platform. But even that, as is evidenced by UTHRs deal, it is short lived. So as I stated over 6 months ago. Sell trading stock hold core. While I will stay long and check in time to time, I question MC's leadership and the cos overall desire to keep SH in the loop. As many have emails that are left in his junk folder. He sees them but doesnt care to responsed. And as for talk about buyout's MC has responsibility to inform us of any reasonable deal that has been brought forth.
|
|
